HSBC Holdings’s C4 Therapeutics CCCC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-13,629
Closed -$70.3K – 2931
2026
Q2
$70.3K Hold
13,629
– – ﹤0.01% 2834
2026
Q1
$36K Hold
13,629
– – ﹤0.01% 2830
2025
Q4
$26.2K Hold
13,629
– – ﹤0.01% 2893
2025
Q3
$30.1K Sell
13,629
-11,528
-46% -$27.7K ﹤0.01% 2665
2025
Q2
$35.6K Sell
25,157
-330
-1% -$480 ﹤0.01% 2956
2025
Q1
$41.3K Buy
25,487
+6,128
+32% +$18.3K ﹤0.01% 2927
2024
Q4
$68.3K Sell
19,359
-1,809
-9% -$9K ﹤0.01% 2952
2024
Q3
$123K Buy
+21,168
New +$127K ﹤0.01% 2760
2024
Q1
– Sell
-30,200
Closed -$171K – 3069
2023
Q4
$171K Sell
30,200
-2,453
-8% -$5.59K ﹤0.01% 2510
2023
Q3
$62K Hold
32,653
– – ﹤0.01% 2606
2023
Q2
$90.3K Buy
32,653
+13,893
+74% +$44.7K ﹤0.01% 2444
2023
Q1
$60.1K Buy
18,760
+8,605
+85% +$50.7K ﹤0.01% 2553
2022
Q4
$58.9K Buy
+10,155
New +$84.2K ﹤0.01% 2954
2022
Q2
– Sell
-10,275
Closed -$251K – 3261
2022
Q1
$251K Buy
+10,275
New +$250K ﹤0.01% 2870

Other funds holding CCCC

HSBC Holdings's CCCC Position: Q3 2026 in Review

HSBC Holdings sold out of C4 Therapeutics (CCCC) in Q3 2026, closing a stake of 13,629 shares — an estimated $70.3K sold.

HSBC Holdings first reported a position in CCCC in Q1 2022 and held it in 14 quarters. The position peaked at $251K in Q1 2022. 152 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

  • HSBC Holdings reported no remaining C4 Therapeutics position as of Q3 2026 after selling out during the quarter.
  • HSBC Holdings sold 13,629 C4 Therapeutics shares in Q3 2026, an estimated $70.3K.
  • HSBC Holdings first reported a position in C4 Therapeutics in Q1 2022 and held it in 14 quarters.
  • HSBC Holdings's C4 Therapeutics position peaked at $251K in Q1 2022.
  • 152 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on HSBC Holdings's 13F filing for Q3 2026, filed 16 Nov 2026.